# EDGAR Filing Document

**Accession Number:** 0001728328
**File Stem:** 0001213900-26-034689
**Filing Date:** 2026-3
**Character Count:** 2172
**Document Hash:** 23b6420f891142e5c63017f551a354c0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-034689.hdr.sgml**: 20260505

**ACCESSION NUMBER**: 0001213900-26-034689

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260326

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** InMed Pharmaceuticals Inc.
- **CENTRAL INDEX KEY:** 0001728328
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 1445-885 WEST GEORGIA ST.
- **CITY:** VANCOUVER
- **STATE:** A1
- **ZIP:** V6C 3E8
- **BUSINESS PHONE:** (604) 669-7207

**MAIL ADDRESS:**
- **STREET 1:** 1445-885 WEST GEORGIA ST.
- **CITY:** VANCOUVER
- **STATE:** A1
- **ZIP:** V6C 3E8

March 26, 2026

**<u>VIA EDGAR</u>**

United States Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549

---

| | |
|:---|:---|
| Re: | **InMed Pharmaceuticals Inc.** |
|  | **Registration Statement on Form S-3** |
|  | **Filed March 20, 2026** |
|  | **File No.: 333-294503** |

---

Dear Ladies and Gentlemen:

Pursuant to Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, InMed Pharmaceuticals Inc. hereby respectfully requests that the effectiveness of the above-referenced Registration Statement on Form S-3 (File No.: 333-294503) be accelerated to occur at 5:00 p.m., New York City time, on March 30, 2026 or as soon thereafter as practicable.

It would be appreciated if you would inform Scott Saks at Norton Rose Fulbright US LLP at +1-212-318-3151 once the above referenced Registration Statement is declared effective.

---

| | | |
|:---|:---|:---|
| Very truly yours, | Very truly yours, | Very truly yours, |
| **InMed Pharmaceuticals Inc.** | **InMed Pharmaceuticals Inc.** | **InMed Pharmaceuticals Inc.** |
| By: | /s/ Netta Jagpal | /s/ Netta Jagpal |
|  | Name: | Netta Jagpal |
|  | Title: | Chief Financial Officer |

---

cc: Scott Saks (Norton Rose Fulbright US LLP)